Search Results

CSL Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.cslseqirus.us/expertise/influenza/pandemic-response-solutions

CSL Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.cslseqirus.us/expertise

CSL Seqirus has received a Biomedical Advanced Research and Development Authority (BARDA) award to complete the fill and finish process for additional pre-pandemic vaccines to further support the U.S. government’s outbreak and preparedness response.

https://www.cslseqirus.us/news/csl-seqirus-announces-sixth-barda-award-in-response-to-avian-influenza

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.cslseqirus.us/news

Biomedical Advanced Research and Development Authority (BARDA) and CSL Seqirus will expand their reserves of MF59® adjuvant to the equivalent of 40 million doses as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).

https://www.cslseqirus.us/news/csl-seqirus-announces-fifth-barda-award-in-response-to-avian-influenza

CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government’s outbreak and preparedness response.

https://www.cslseqirus.us/news/csl-seqirus-announces-us-government-award-in-response-to-avian-influenza

CSL Seqirus will deliver further H5N8 A/Astrakhan antigen to support the U.S. government's pandemic preparedness activities

https://www.cslseqirus.us/news/csl-seqirus-announces-third-us-government-award-in-relation-to-influenza-a-h5n8-candidate-vaccine

CSL Seqirus, as a member of the CSL group, is bound by CSL's Code of Responsible Business Practice. Access our annual financial and diversity disclosures.

https://www.cslseqirus.us/our-company/corporate-responsibility/disclosures

CSL Seqirus will manufacture and clinically assess a cell-based, adjuvanted pre-pandemic influenza vaccine candidate to support the U.S. government’s pandemic preparedness activities

https://www.cslseqirus.us/news/csl-seqirus-us-government-award-to-manufacture-and-assess-influenza-a-h5n8-pre-pandemic-vaccine

CSL Seqirus is the only manufacturer to offer a differentiated influenza vaccine portfolio for all eligible age groups in the U.S.

https://www.cslseqirus.us/news/csl-seqirus-commences-shipping-its-portfolio-of-influenza-vaccines